DE602006014798D1 - Vorrichtung und Verfahren zur Unterscheidung zwischen akuter und chronischer Myokardial-Nekrose bei symptomatischen Patienten - Google Patents

Vorrichtung und Verfahren zur Unterscheidung zwischen akuter und chronischer Myokardial-Nekrose bei symptomatischen Patienten

Info

Publication number
DE602006014798D1
DE602006014798D1 DE602006014798T DE602006014798T DE602006014798D1 DE 602006014798 D1 DE602006014798 D1 DE 602006014798D1 DE 602006014798 T DE602006014798 T DE 602006014798T DE 602006014798 T DE602006014798 T DE 602006014798T DE 602006014798 D1 DE602006014798 D1 DE 602006014798D1
Authority
DE
Germany
Prior art keywords
acute
sample
subject
determining
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006014798T
Other languages
English (en)
Inventor
Georg Prof Dr Hess
Andrea Dr Horsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Publication of DE602006014798D1 publication Critical patent/DE602006014798D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
DE602006014798T 2006-03-24 2006-03-24 Vorrichtung und Verfahren zur Unterscheidung zwischen akuter und chronischer Myokardial-Nekrose bei symptomatischen Patienten Active DE602006014798D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06111716A EP1837659B1 (de) 2006-03-24 2006-03-24 Vorrichtung und Verfahren zur Unterscheidung zwischen akuter und chronischer Myokardial-Nekrose bei symptomatischen Patienten

Publications (1)

Publication Number Publication Date
DE602006014798D1 true DE602006014798D1 (de) 2010-07-22

Family

ID=36129718

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006014798T Active DE602006014798D1 (de) 2006-03-24 2006-03-24 Vorrichtung und Verfahren zur Unterscheidung zwischen akuter und chronischer Myokardial-Nekrose bei symptomatischen Patienten

Country Status (9)

Country Link
US (1) US7732214B2 (de)
EP (2) EP1837659B1 (de)
JP (1) JP4944185B2 (de)
CN (1) CN101410716A (de)
AT (1) ATE470862T1 (de)
CA (1) CA2646245A1 (de)
DE (1) DE602006014798D1 (de)
ES (1) ES2344993T3 (de)
WO (1) WO2007110359A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1890154B1 (de) * 2006-08-16 2012-07-04 F. Hoffmann-La Roche AG Herztroponin als Indikator für fortgeschrittene Koronararterienerkrankung und deren Komplikationen
WO2009047285A1 (en) * 2007-10-10 2009-04-16 Roche Diagnostics Gmbh Natriuretic peptide/troponin ratio for the assessment of preexisting myocardial dysfunction in patients with acute coronary syndrome
WO2010010155A1 (en) * 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Monitoring anti-angiogenesis therapy
WO2010043393A1 (en) * 2008-10-17 2010-04-22 Roche Diagnostics Gmbh Use of biglycan in the assessment of heart failure
WO2011012268A1 (en) * 2009-07-27 2011-02-03 Roche Diagnostics Gmbh Use of mimecan in the assessment of heart failure
EP2499489B1 (de) * 2009-11-13 2015-01-07 BG Medicine, Inc. Risikofaktoren und vorhersage von myokardinfarkt
EP2336784B1 (de) * 2009-12-18 2017-08-16 Roche Diagnostics GmbH GDF-15 und/oder Troponin T zur Prognose von Nierenausfällen bei Herzinsuffizienzpatienten
US20110306148A1 (en) 2010-06-14 2011-12-15 Siemens Healthcare Diagnostics Inc. Composition for use as an assay reagent
EP2786154B1 (de) 2011-12-01 2017-11-01 Roche Diagnostics GmbH Nt-pro-anp und nt-pro-bnp zur diagnose eines schlaganfalls
KR101531835B1 (ko) * 2013-10-16 2015-06-29 한국표준과학연구원 화학적 동위원소 치환법을 이용한 혈액 내 뇌성 나트륨 이뇨 펩타이드 질량분석법
JP6985517B2 (ja) * 2017-09-30 2021-12-22 アルフレッド ヘルス 予後予測方法
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
US7632647B2 (en) * 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
AU2002305394A1 (en) * 2001-05-04 2002-11-18 Biosite, Inc. Diagnostic markers of acute coronary syndromes and methods of use thereof
US6461828B1 (en) * 2001-09-04 2002-10-08 Syn X Pharma Conjunctive analysis of biological marker expression for diagnosing organ failure
US7109023B2 (en) * 2002-11-18 2006-09-19 Princeton Biomeditech Corporation Immunossay device for diagnosing congestive heart failure and predicting mortality in congestive heart failure patients
CA2511269A1 (en) * 2004-07-07 2006-01-07 F. Hoffmann-La Roche Ag Multimarker panel based on p1gf for diabetes type 1 and 2
EP1731910A1 (de) * 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Gebrauch von NT-proANP und NT-proBNP für die Diagnose von Herzkrankheiten

Also Published As

Publication number Publication date
EP1999475A1 (de) 2008-12-10
WO2007110359A1 (en) 2007-10-04
EP1837659B1 (de) 2010-06-09
US20090087918A1 (en) 2009-04-02
CA2646245A1 (en) 2007-10-04
JP4944185B2 (ja) 2012-05-30
ATE470862T1 (de) 2010-06-15
CN101410716A (zh) 2009-04-15
JP2009536726A (ja) 2009-10-15
US7732214B2 (en) 2010-06-08
ES2344993T3 (es) 2010-09-13
EP1837659A1 (de) 2007-09-26

Similar Documents

Publication Publication Date Title
DE602006014798D1 (de) Vorrichtung und Verfahren zur Unterscheidung zwischen akuter und chronischer Myokardial-Nekrose bei symptomatischen Patienten
ATE511656T1 (de) Verfahren zur risikobewertung von herzeingriffen auf gdf-15-basis
ATE452343T1 (de) Verbesserte vitamin-d-messung
ATE493649T1 (de) Verfahren zur diagnose von polyzystischer nierenkrankheit
MY149843A (en) Method for quantifying reservoir connectivity using fluid travel times
ATE473446T1 (de) Verfahren und testvorrichtungen zur unterscheidung verschiedener formen von krankheiten und leiden, die durch thrombocytopenia und/oder durch spontane interaktionen zwischen dem von-willebrand-faktor und plättchen gekennzeichnet sind
WO2008095492A3 (en) A method for diagnosing atherosclerotic plaques by measurement of cd36
ATE489482T1 (de) Verfahren zur herstellung von hybridsubstraten mit dna und antikörpern sowie verwendungen davon
DE112006001755A5 (de) EU/TB-Chelat-basiertes fluoreszenzspektroskopisches Verfahren zum Nachweis von Analyten
ATE548467T1 (de) Verfahren zur identifizierung von biomarkern mit eignung bei der diagnose biologischer zustände
WO2010033371A3 (en) Molecular markers for lung and colorectal carcinomas
DE602006017058D1 (de) Verfahren zur stratifizierung von herzinsuffizienz
WO2007030949A3 (en) Methods of diagnosing ovarian cancer and kits therefor
WO2005071407A3 (en) Methods of diagnosing acute coronary syndrome by measuring urotensin ii
ATE523780T1 (de) Verfahren zum bestimmen und bewerten von wirbelstromanzeigen, insbesondere von rissen, in einem prüfgegenstand aus einem elektrisch leitfähigen material
ATE519116T1 (de) Verfahren zur normierung der konzentration von analyten in einer urinprobe
WO2009104974A3 (en) Biomarkers for acute coronary disorder
WO2009047283A3 (en) Means and methods for monitoring myocardial infarction and its treatment
EP3178846A3 (de) Neuartige phosphorylierung von kardialem troponin i als ein monitor einer kardialen verletzung
DK1664793T3 (da) Neurotoksisk aminosyre eller neurotoksisk derivat deraf forbundet med neurologiske lidelser
DE502005006527D1 (de) Verfahren zur Herstellung von hoch belastbaren Bauteilen durch Präzisionsschmieden
DE602006010705D1 (de) Biochemische Marker für akute Lungenembolie
DE60320534D1 (de) Verfahren zur qualitätskontrolle einer kräutermedizin
WO2010138610A3 (en) Novel desmin phosphorylation sites useful in diagnosis and intervention of cardiac disease
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome